Navigation Links
DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
Date:3/11/2009

SAN DIEGO, March 11 /PRNewswire/ -- Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologic delivery system developed by MediVas LLC, a San Diego based biomedical company. Integrated into DSM's Trancerta(R) Drug Delivery platform, this will open up a broad range of opportunities for next generation drug delivery. DSM's activities in this field are a perfect illustration of the way DSM is leveraging its competences in Materials Sciences into Life Sciences applications.

MediVas' technology for the delivery of biologics and drugs is based on a next generation set of polymers exclusively licensed from Cornell University. Generated from research both at Cornell and at MediVas, the company has an IP portfolio containing over 60 issued or pending US patents. The polymers are biodegradable, biocompatible and bioabsorbable. Furthermore they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload.

The technology can be used with a diverse group of drug candidates, from proteins, peptides and nucleic acids to small molecule drugs, thus expanding the possible application areas of DSM's Trancerta(R) platform. The license DSM obtained applies for the development of drug delivery systems aimed at treating ophthalmic, (cardio)vascular, musculoskeletal diseases and at providing general pain relief. MediVas will focus its development efforts on nanoparticle based therapies in oncology, immunology and on the delivery of nucleic acids.

"Through this deal we bring in the first biodegradable polymer into DSM's Biomedical portfolio, which significantly enhances our materials competences. This will help us realize our ambition to build a portfolio of drug d
'/>"/>

SOURCE MediVas LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
3. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
6. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
7. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
10. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
11. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... "Telemedicine and Mobile Healthcare Solutions, Services, and ... report to their offering. ... terms that pertain to the use of telecommunications ... clinical/non-clinical healthcare services. They form the ecosystem that ...
(Date:3/3/2015)... RADNOR, Pa. , March 3, 2015 /PRNewswire/ ... of laboratory products, services and solutions, announced today ... England Biolabs®, Inc. (NEB®). This agreement allows VWR ... renowned technical support in the U.S. and Puerto ... to NEB,s products through VWR,s e-business platform, sales ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3VWR Announces Expansion of Distribution Agreement with New England Biolabs 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
(Date:3/4/2015)... Professionals with disabilities are eager to ... companies, according to a new Think Beyond the Label ... 235 professionals with disabilities , respondents also say they ... including ones that are geared to people with disabilities, ... ,     Online job search tools are used by ...
(Date:3/4/2015)... 04, 2015 The medical device landscape ... management forgot – or ignored or didn't know – ... market based on physician input before proceeding to design ... specifically, founders – become so enamored of an innovative ... Will physicians use the device?” says Dr. Kathryn ...
(Date:3/3/2015)... Anik Singal's Profit Academy - ... marketers has become the talk of the town ... surrounding the course's general release has garnered the ... her to review the program's content and publish ... biggest keys to success with Internet marketing is ...
(Date:3/3/2015)... March 03, 2015 On February 21st, ... the fabulous EcoLuxe Lounge, a day-long event that features ... conscious products and services. Organized by Debbie Durkin and ... film placement producer, the EcoLuxe Lounge saw many notable ... roles on General Hospital, The Flash, Star Trek: Deep ...
(Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
Breaking Medicine News(10 mins):Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
... could actually be caused as a result of a defect ... after scientists have worked towards identifying important skin cancer genes ... scientists to look at thousands of genes at once, helping ... greater detail. There are over 200 different types of cancer ...
... ketoacidosis (DKA) is a life-threatening condition that frequently ... The critical factors in the treatment of DKA ... skillful fluid and electrolyte adjustment, and the initiation ... fluid volume has been achieved. Continuous low-dosage intravenous ...
... Anderson Cancer Center have found that weight gain or ... of prostrate cancer. ,The report is detailed in ... Research, corroborates findings of an earlier research that had ... Strom, Ph.D., an associate professor in the Department of ...
... Phase II study to 12 months confirm the significant effects ... patients with relapsing multiple sclerosis (MS). ,The data, ... both patient groups taking FTY720 (1.25 mg and 5 mg) ... of more than 50% during the first six months of ...
... chronic illness that requires continuing medical care and ... to reduce the risk of long-term complications//. As ... care practitioners are confronted with an ever-increasing tide ... Undiagnosed chronic kidney disease (CKD) is common in ...
... an ancient myth that coco bean can be used to treat ... limit the development of fluids that cause diarrhea//. ,The use ... 16th century by ancient South American and European cultures. Until now, ... bean or more specifically why it has been used in the ...
Cached Medicine News:Health News:Novartis MS Drug Shows Promising Results 2Health News:Novartis MS Drug Shows Promising Results 3
... simple, effective method for determining color vision ... data which can be applied to many ... set consists of four trays containing a ... that have incremental hue variation on one ...
... D15 test evaluation has a choice ... caps with automatic creation 'horse-shoe' diagrams, ... deficiency analysis, calculation of color confusion ... eye selection (OD, OS, OU) and ...
... Farnsworth D15 test is used ... color defect vs normal. Farnsworth ... which permit the patient to ... Then the box is closed ...
HRR/Amsler book combo with occluding glasses....
Medicine Products: